GMAB News and Press, Genmab A/S From 08/03/23

2023-08-03 17:58:02 ET Genmab A/S (GMAB) Q2 2023 Earnings Conference Call August 3, 2023 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Judith Klimovsky - Chief Development Officer Anthony M...

2023-08-03 11:06:41 ET Genmab press release ( GMAB ): 1H GAAP EPS of DKK20.61. Revenue of DKK4.2B (+32.9% Y/Y). For further details see: Genmab GAAP EPS of DKK20.61, revenue of DKK4.2B

August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab- bysp ) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody t...

2023-08-02 11:44:06 ET Genmab ( GMAB ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is $0.23 and the consensus Revenue Estimate is $600.62M Over the last 3 months, EPS estimates have seen 0 upward re...

2023-07-28 03:14:44 ET Genmab ( GMAB ) expects 34% Y/Y growth in H1 2023 revenue to reach DKK 7.05B, with operating expenses expected to jump 45% to DKK 5.12B. This gives a 10% boost to operating profit, touching DKK 1.93B. Genmab ( GMAB ) also lays down 2023 FY ...

Company Announcement COPENHAGEN , Denmark; July 2 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. ...

Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) ...

2023-07-20 07:37:43 ET Genmab ( GMAB ) said that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous product as reported by Johnson & Johnson were $2,431M in Q2 2023. Net trade sales were $1,322M in the U.S. and $1,1...

2023-07-20 07:07:34 ET Johnson & Johnson ( NYSE: JNJ ) added ~2% in the pre-market Thursday after the pharma giant exceeded Wall Street forecasts with its Q2 2023 results, thanks mainly to better-than-expected results from its Pharmaceutical and MedTech segments. The New...

Company Announcement Net sales of DARZALEX ® in the second quarter of 202 3 totaled USD 2,431 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 20...